Literature DB >> 16445116

Drug withdrawals and the lessons within.

Dennis A Smith1, Esther F Schmid.   

Abstract

Drug withdrawals over recent decades have triggered changes in the way that drug targets and screening programs are researched and designed. In the cases having the greatest impact, the reason for withdrawal was the reversible interaction of a drug or its metabolite with a single receptor, ion channel or enzyme (primary or secondary pharmacology). Once this interaction is identified, screens can be established and validated. When the mechanism is complex (eg, organ toxicity), however, such screens are difficult to implement and usually examine only the initial step, leading to considerable problems in extrapolation and risk definition. This review classifies drugs withdrawn from the US market over the last 25 years by their reasons for withdrawal, and examines how drug discovery programs have been modified in response to these events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16445116

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  17 in total

Review 1.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 2.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

Review 3.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.

Authors:  Marina A Dobrovolskaia; Scott E McNeil
Journal:  J Control Release       Date:  2013-06-03       Impact factor: 9.776

4.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

Review 5.  Quinolones: review of psychiatric and neurological adverse reactions.

Authors:  Ana M Tomé; Augusto Filipe
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

6.  Chemical toxicity testing in vitro using cytochrome P450-expressing cell lines, such as human CYP1B1.

Authors:  Robert Landsiedel; Eric Fabian; Tewes Tralau; Andreas Luch
Journal:  Nat Protoc       Date:  2011-04-28       Impact factor: 13.491

7.  Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.

Authors:  Jeanne M Connolly; Marina A Bakay; James T Fulmer; Robert C Gorman; Joseph H Gorman; Mark A Oyama; Robert J Levy
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

8.  Quinolone antibiotics and suicidal behavior: analysis of the World Health Organization's adverse drug reactions database and discussion of potential mechanisms.

Authors:  Julie Samyde; Pierre Petit; Dominique Hillaire-Buys; Jean-Luc Faillie
Journal:  Psychopharmacology (Berl)       Date:  2016-04-26       Impact factor: 4.530

Review 9.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

Review 10.  Pharmacogenomics in clinical practice and drug development.

Authors:  Andrew R Harper; Eric J Topol
Journal:  Nat Biotechnol       Date:  2012-11-08       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.